Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-immunotherapy combinations in metastatic pancreatic adenocarcinoma
NCT04787991Phase 1Completed
- Sponsor
- Cancer Insight
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Monoclonal Antibodies, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab, hydroxychloroquine and NG-350A in pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Cancer Insight. Primary endpoint: Adverse Events at 2.5 years. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04787991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787991.